

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE

05 AUG 15 PM 2:55

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name

Ryan, Phillips, Utrecht, & MacKinnon

2. Address Check if different than previously reported

1133 Connecticut Avenue, NW, Suite 300

3. Principal Place of Business (if different from line 2)

City: Washington State/Zip (or Country) DC 20036

4. Contact Name

Telephone

E-mail (optional)

5. Senate ID #

Rodney Hoppe

202-293-1177

30187-631

7. Client Name Self

6. House ID #

Pfizer Inc.

30680039

TYPE OF REPORT 8. Year 2005 Midyear (January 1-June 30) OR Year End (July 1-December)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report Termination Date _____ 11. No Lobbying

INCOME OR EXPENSES – Complete Either Line 12 OR Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000

\$10,000 or more \$ 60,000
~~income (nearest \$20,000)~~

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000

\$10,000 or more \$ _____
~~Expenses (nearest \$20,000)~~

14. REPORTING METHOD. Check box to indicate the accounting method. See instructions for description of method.

Method A. Reporting amounts using LDA definition

Method B. Reporting amounts under section 6033(c) Internal Revenue Code

Method C. Reporting amounts under section 162(e) Internal Revenue Code

Signature Rodney Hoppe

8.12.05

Printed Name and Title Rodney Hoppe, Partner

Registrant Name Ryan, Phillips, Utrecht & MacKinnon

Client Name Pfizer Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the reg engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

- H.R. 563, Prescription Drug Affordability Act of 2005
- H.R. 753/S. 184, Safe IMPORT Act of 2005, provisions dealing with pharmaceuticals
- H.R. 5/S. 1355, Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2005
- S. 455, Medicare Prescription Drug Price Reduction Act of 2005
- H. 376, Medicare's Equitable Drugs for Seniors Act of 2005
- H.R. 1626, Medicare Prescription Drug Improvement Act
- S. 239, Medicare Enhancements for Needed Drugs Act of 2005
- H.R. 752, S. 873, Medicare Prescription Drug Savings and Choice Act of 2005

17. House(s) of Congress and Federal Agencies contacted Check if None

- U.S. House
- U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Matt Berzok	
Rodney Hoppe	
Jeffrey M. MacKinnon	
William D. Phillips	
Mark Planning	
Thomas M. Ryan	
Joseph V. Vasapoli	
William Brooke	
Gregg Renkes	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature Rodney Hoppe Date 8-12-05

00000380592

Registrant Name Ryan, Phillips, Utrecht & MacKinnon

Client Name Pfizer Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the reg engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (One per page)

16. Specific lobbying issues

- Legislation on issues pertaining to proposed Medical Prescription Drug Benefits.
- Legislation on issues regarding FDA regulation of prescription drugs.
- Congressional Oversight of Drug Safety

- S. 109/H.R. 328, Pharmaceutical Market Access Act of 2005
- H.R. 700/S. 334, Pharmaceutical Market Access and Drug Safety Act of 2005

00000380593

17. House(s) of Congress and Federal Agencies contacted Check if None

- U.S. House
- U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Matt Berzok	
Rodney Hoppe	
Jeffrey M. MacKinnon	
William D. Phillips	
Mark Planning	
Thomas M. Ryan	
Joseph V. Vasopoli	
William Brooke	
Gregg Renkes	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature *Rodney Dopper*

Date *8.12.08*



Printed Name and Title Rodney Hoppe- Partner

00000380594

